EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients (EBVER/TMC)

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Andreas Arnold, University Hospital, Basel, Switzerland

ClinicalTrials.gov Identifier:

NCT01942005

First received: August 7, 2013

Last updated: December 3, 2014

Last verified: December 2014

History of Changes

Purpose

Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

Condition
Immunosuppression Neoplasm


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients,Especially Patients After Organ Transplantation and Patients With HIV Infection

Further study details as provided by Andreas Arnold, University Hospital, Basel, Switzerland:

Primary Outcome Measures:

Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen. [ Time Frame: 7 years ]

Secondary Outcome Measures:

correlation between possibly detected mutation/specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen and a composite of kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression. [ Time Frame: 7 years ]

Biospecimen Retention: Samples With DNA

Blutsample


Enrollment:	144
Study Start Date:	January 2010
Study Completion Date:	May 2014
Primary Completion Date:	May 2014 (Final data collection date for primary outcome measure)

Detailed Description:

correlation between possibly detected mutation/specific polymorphism and kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

patients who underwent organ transplatation or patients who have a HIV infection

Criteria

Inclusion Criteria:

patients in an immunosuppressive condition either by immunosuppressants or by HIV infection

Exclusion Criteria:

written informed consent not given

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01942005

Locations


Switzerland
University Hospital Basel, Dermatology
Basel, Basel Stadt, Switzerland, 4031

Sponsors and Collaborators

Andreas Arnold

Investigators


Principal Investigator:	Andreas Arnold, MD	University Hospital Basel, Dermatology, CH-4031 Basel

More Information


Responsible Party:	Andreas Arnold, Dr. med. Andreas Arnold, senior physician, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:	NCT01942005 History of Changes
Other Study ID Numbers:	11/10
Study First Received:	August 7, 2013
Last Updated:	December 3, 2014

ClinicalTrials.gov processed this record on July 28, 2017

To Top